| Biotechnology Industry | Healthcare Sector | - CEO | TWSE Exchange | TW0004131008 ISIN |
| Taiwan Country | - Employees | - Last Dividend | 29 Dec 2021 Last Split | - IPO Date |
NeoCore Technology Co., Ltd., originally established in 1987 under the name DR. Chip Biotechnology Incorporation, underwent a rebranding in July 2023 to its current identity. Headquartered in Tainan, Taiwan, the company has carved a niche for itself in the biotechnology sector with its focus on the design, manufacture, and sale of biochips and rapid nucleic acid hybridization devices. Expertise in this area has allowed NeoCore Technology to contribute significantly to various fields including food safety, human diagnosis, and agriculture through its innovative products. Additionally, the company takes its capability a step further by offering laboratory planning, design, and other services, encompassing a wider aspect of the biotechnological research and development process. Notably, it also diversifies its product range by engaging in the wholesale and retail of contact lenses, showcasing its adaptability and broad market approach.
In addition to these products, NeoCore Technology extends its service offerings to include comprehensive laboratory planning, design, and a suite of other services aimed at enhancing laboratory operations and efficiency. Moreover, the company's involvement in the retail and wholesale of contact lenses indicates its venture into healthcare products, broadening its impact on the market.